Successful Treatment of Severe Atopic Dermatitis and Alopecia Universalis With Upadacitinib in a 29-Year-Old Male Patient

A 29-year-old male with severe atopic dermatitis (AD) and alopecia universalis (AU) showed significant improvement after treatment with upadacitinib, a JAK1 inhibitor. Despite previous unsuccessful treatments with methotrexate and cyclosporine, upadacitinib led to a marked reduction in AD severity scores (SCORAD and EASI) and partial control of AU, as indicated by a decrease in the SALT score. The treatment was well-tolerated, with minor side effects like folliculitis and acne, and resulted in improved quality of life. This case suggests that upadacitinib could be a promising option for patients with severe AD and autoimmune conditions like AA, offering clinical efficacy and a good safety profile.